Scholars Central

Conference abstractPublished 2018

A completely novel long-acting GLP-1 receptor agonist, glutazumab

Authors: Caina Li, Zhufang Shen, Xiaofeng Wang, Cheng Zhang

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

GLP-1-based drugs have been proposed as a mono- or combined therapy for type 2 diabetes mellitus for the outstanding features, but natural GLP-1 is hardly used in clinic due to its short half-life, while short-acting analogs/receptor agonists have poor compliance in patients for frequent dosing. This study aims to introduce a novel long-acting GLP-1 receptor agonist, which is an antibody fusion protein by linking the human GLP-1 derivative to a humanized GLP-1R antibody via a peptide linker, and to evaluate its anti-diabetic effects and duration. Glutazumab is characterized by receptor binding and reporter gene assay, and its specificity was investigated through addition of exendin (9-39) and Ab1 which were the cognate receptor antagonist and antibody respectively. To evaluate the anti-diabetic effects, glutazumab was studied in diabetic KKAy mice by single dose and repeated doses. The blood glucose, food/water intake, body weight and gastric emptying was measured in the single dose study, while blood glucose, GSP, HbA1c, insulin and lipid were determined in the repeated-dose study. The oral glucose tolerance and hyperglycemic clamp test were performed to assess the β-cell function. In all the experiments, dulaglutide served as a control. Glutazumab significantly binds and activates GLP-1R, while the natural receptor antagonist exendin (9-39) showed no inhibition except in the presence of the antibody Ab1. Single injection of Glutazumab remarkably decreased blood glucose for 3~6 days in normal ICR mice and diabetic KKAy mice. Repeated injections of glutazumab also evidently reduced non-fasting and fasting blood glucose fluctuation, decreased GSP and HbA1c levels, improved impaired oral glucose tolerance and β-cell function and ameliorated the dyslipidemia in diabetic KKAy mice. These results demonstrated that glutazumab is a novel long-acting GLP-1 receptor agonist with excellent anti-diabetic effect in KKAy mice, and suggested that it may be a potential treatment for type 2 diabetes. Recent Publications 1. Caina Li, Miaomiao Yang and Xiaofeng Wang, et al. (2018) Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites. Biochemical Pharmacology 150:46-53. 2. Caina Li, Shaocong Hou, Shuainan Liu, et al. (2017) The albumin-exendin-4 recombinant protein E2HSA improves glycemic control and β-cell function in spontaneous diabetic KKAy mice. BMC Pharmacology and Toxicology 18(1):4856. 3. Caina Li, Miaomiao Yang, Guojiang Hou, Yi Huan, et al. (2017) A human glucagon-like peptide-1-albumin recombinant protein with prolonged hypoglycemic effect provides efficient and beneficial control of glucose metabolism in diabetic mice. Biol Pharm Bull. 40(9):1399-1408. 4. Guojiang Hou, Caina Li, Yi Huan, et al. (2017) The PI3K/Akt1-Foxo1 translocation pathway mediates Exf effects on NIT1 cell survival. Exp Clin Endocrinol Diabetes 125(10):669-676. 5. Caina Li, Sujuan Sun and Zhufang Shen (2015) Determination of serum acetaminophen based on the diazo reaction and its application in the evaluation of gastric emptying. Acta Pharmaceutica Sinica. 50(5):560-564.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Diabetes & Metabolism.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Diabetes & Metabolism
  • SubjectDiabetes & Endocrinology
  • BylineArticles whose byline prints “Caina Li”
  • BylineArticles whose byline prints “Zhufang Shen”
  • BylineArticles whose byline prints “Xiaofeng Wang”
  • BylineArticles whose byline prints “Cheng Zhang”